spacer
home > epc > spring 2002 > uk and european biotechs - partnering for profit
PUBLICATIONS
European Pharmaceutical Contractor

UK and European Biotechs - Partnering for Profit

The British biotech sector may be providing many globally-important technological answers, but it is also continuing to question how best to find and work with others in both discovery and development. No biotechnology company, however big, can completely go it alone. Getting together with US partners has often been the route for UK companies but as this article emphasises, there are wonderful opportunities in Europe and it is just as easy to cross the Channel as the Atlantic.

Whether their goal is technological, commercial, manufacturing or marketing know-how, partnerships are proving invaluable in the battle for biotech survival and added value. With an increasingly complex market, and with the time to achieve critical mass and gain entry to market continually shortening, I think it is inevitable that the search for appropriate alliances will continue to rise inexorably up the agenda. Despite its many strengths, this search is especially important for the UK biotech sector. While we in the UK are deservedly renowned for the innovative excellence of our basic ideas, it has also been known for others to get these ideas to market first and reap the rewards. Partnerships can help us to avoid this scenario.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Philip Oliver, International Technology Promoter, Life Sciences - Europe

The first International Technology Promoter with a specific European life sciences focus, Philip Oliver calls on his wide-ranging involvement with the biotechnology, pharmaceutical and related industries to promote partnerships with the UK. As a biotech business development specialist with 12 years' experience of working in the US and Europe, Philip has expertise in the areas of environment, health, safety, quality management, project management and toxicology.

Before joining Pera, Philip was European Manager of Business Development for a leading pharmaceutical and biotechnology research organisation. He has also held posts in the chemical and oil industry. Philip has a BSc with Associateship of the Royal College of Science from Imperial College, London and is involved with the biotech special interest group of the Drug Information Association.

spacer
Philip Oliver
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nova Biomedical Launches BioProfile® FLEX2 On-Line Autosampler for Fully Automated Sampling, Analysis, and Feedback Control of up to 10 Bioreactors

Waltham, MA – Nova Biomedical is pleased to announce the launch of the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to 3 weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement